Wall Street brokerages expect ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) to post earnings of ($0.08) per share for the current quarter, according to Zacks Investment Research. Zero analysts have issued estimates for ZIOPHARM Oncology’s earnings, with the highest EPS estimate coming in at ($0.07) and the lowest estimate coming in at ($0.09). ZIOPHARM Oncology reported earnings of ($0.12) per share in the same quarter last year, which would suggest a positive year-over-year growth rate of 33.3%. The firm is scheduled to issue its next quarterly earnings results on Wednesday, August 14th.
On average, analysts expect that ZIOPHARM Oncology will report full year earnings of ($0.33) per share for the current year, with EPS estimates ranging from ($0.33) to ($0.32). For the next year, analysts expect that the business will report earnings of ($0.18) per share, with EPS estimates ranging from ($0.30) to $0.05. Zacks’ earnings per share averages are an average based on a survey of sell-side analysts that that provide coverage for ZIOPHARM Oncology.
ZIOPHARM Oncology (NASDAQ:ZIOP) last released its quarterly earnings data on Wednesday, May 8th. The biotechnology company reported ($0.08) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.09) by $0.01.
Shares of NASDAQ ZIOP traded down $0.02 during trading on Wednesday, reaching $5.69. 8,080 shares of the company traded hands, compared to its average volume of 2,554,339. The company has a fifty day moving average price of $5.15. The firm has a market cap of $921.13 million, a PE ratio of -11.91 and a beta of 2.66. ZIOPHARM Oncology has a 12-month low of $1.56 and a 12-month high of $6.30. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.89 and a current ratio of 8.89.
A number of large investors have recently bought and sold shares of the business. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. increased its stake in ZIOPHARM Oncology by 12.3% during the 1st quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 52,871 shares of the biotechnology company’s stock worth $204,000 after buying an additional 5,802 shares in the last quarter. Legal & General Group Plc boosted its holdings in shares of ZIOPHARM Oncology by 30.6% during the 4th quarter. Legal & General Group Plc now owns 25,865 shares of the biotechnology company’s stock worth $48,000 after purchasing an additional 6,054 shares during the last quarter. SG Americas Securities LLC boosted its holdings in shares of ZIOPHARM Oncology by 30.8% during the 1st quarter. SG Americas Securities LLC now owns 31,906 shares of the biotechnology company’s stock worth $123,000 after purchasing an additional 7,506 shares during the last quarter. Northern Trust Corp boosted its holdings in shares of ZIOPHARM Oncology by 0.5% during the 4th quarter. Northern Trust Corp now owns 1,647,754 shares of the biotechnology company’s stock worth $3,081,000 after purchasing an additional 8,068 shares during the last quarter. Finally, Harel Insurance Investments & Financial Services Ltd. acquired a new position in shares of ZIOPHARM Oncology during the 1st quarter worth approximately $35,000. Institutional investors own 38.75% of the company’s stock.
About ZIOPHARM Oncology
ZIOPHARM Oncology, Inc, a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of immuno-oncology therapies for treating heterogenous solid tumors and unknown antigens. The company develops two immuno-oncology platform technologies, including Sleeping Beauty (SB), which is based on the genetic engineering of immune cells using a non-viral transposon/transposase system to reprogram T-cells outside of the body for infusion; and Controlled IL-12, which delivers interleukin 12 or IL-12, a master regular of the immune system, in a controlled and safe manner to focus the patient's immune system to attack cancer cells.
Featured Story: How are the companies in the S&P 500 selected?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ZIOPHARM Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology and related companies with MarketBeat.com's FREE daily email newsletter.